Home » Authors » Mark McCarty

Articles by Mark McCarty

Trials difficult, but needed, for CAD validity vs. human reader

March 13, 2008

By Mark McCarty

MedPAC on Medicare: Medicare FFS plans reported as costlier than oft-criticized MA

March 13, 2008

By Mark McCarty

FDA Amendment’s effects will take time to impact industry

March 12, 2008

By Mark McCarty

Boosters of personalized medicine wary of hyperbole, public backlash

March 11, 2008

By Mark McCarty

Stand-alone and reader tests required for PMAs for CAD

March 7, 2008

By Mark McCarty

FDA & industry say current regulations enough for nano

March 6, 2008

By Mark McCarty

IOM panel: colorectal cancer testing lags despite coverage

March 6, 2008

By Mark McCarty

Trials difficult, but needed, for CAD validity vs. human reader

March 6, 2008

By Mark McCarty

Washington roundup: Medicare fraud effort blasted as federal program ‘run amok’

March 4, 2008

By Mark McCarty

FDA chief says much needed to meet ‘jet stream’ of change

March 4, 2008

By Mark McCarty

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...